Tamoxifen and TGF-beta in Breast Tumor Fibroblasts
Author Information
Author(s): JR Benson, LM Wakefield, M Baum, AA Colletta
Primary Institution: The Royal Marsden Hospital
Hypothesis
Tamoxifen may stimulate fibroblasts to produce transforming growth factor beta (TGF-beta) independently of estrogen receptors.
Conclusion
Tamoxifen increases the synthesis of TGF-beta in breast tumor fibroblasts, but does not consistently enhance its secretion.
Supporting Evidence
- Tamoxifen treatment did not induce a consistent increase in TGF-beta secretion.
- Benign breast tumor fibroblasts secreted significantly higher levels of TGF-beta2 compared to malignant fibroblasts.
- Immunofluorescence showed increased intracellular TGF-beta in tamoxifen-treated fibroblasts.
Takeaway
This study shows that tamoxifen can make certain cells in the breast produce a growth factor that can help control cancer, but it doesn't always help those cells release it.
Methodology
Primary cultures of fibroblasts from malignant and benign breast tumors were treated with tamoxifen, and TGF-beta secretion was measured using immunoassays.
Limitations
The study is based on in vitro data, which may not fully represent in vivo conditions.
Participant Demographics
Fibroblast strains derived from patients with malignant and benign breast tumors, including a strain from normal skin.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website